The effect of interleukin-1 receptor antagonist on arteries and cholesterol metabolism

Journal of Atherosclerosis and Thrombosis

Volumn 13, Issue 1, 2006, Pages 21-30

  Isoda, Kikuo ^a   Ohsuzu, Fumitaka ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Atherogenesis; Cholesterol metabolism; Inflammation; Interleukin 1 receptor antagonist

Indexed keywords

CHOLESTEROL; IL1RN PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; SIALOGLYCOPROTEIN;

ANIMAL; ATHEROSCLEROSIS; DRUG EFFECT; HUMAN; INTIMA; METABOLISM; PATHOLOGY; REVIEW;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS; TUNICA INTIMA;

EID: 33745778310     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.13.21     Document Type: Review

References (76)

1. Dinarello CA: Biology of interleukin 1. FASEB J, 2: 108-115, 1988
2. DiGiovine FS and Duff GW: Interleukin-1: the first interleukin. Immunol Today, 11: 13-20, 1990
3. Tocci, MJ and Schmidt JA: Interleukin-1: Structure and function. In Cytokines in health and disease, second edition. Pp1-27, Marcel Dekker, 1997
4. Dinarello CA: Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol, 16: 457-499, 1998
5. Arend WP: The balance between IL-1 and IL-Ra in disease. Cytokine Growth Factor Rev, 13: 323-340, 2002
6. Horai R, Asano M, Sudo K, Kanuka H, Suzuki M, Nishihara M, Takahashi M, and Iwakura Y: Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocoticoid secretion. J Exp Med, 187:1463-1475, 1998
7. Matsuki T, Horai R, Sudo K, and Iwakura Y: IL-1 plays an important role inlipid metabolism by regulating insulin levels under physiological conditions. J Exp Med, 198: 877-888, 2003
8. Dzau, VJ, Braun-Dullaeus RC, and Sedding DG: Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nat Med, 8: 1249-1256, 2002
9. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, and Gimbrone MA: Interleukin 1 induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med, 160: 618-623, 1984
10. Libby P, Ordovas JM, Birinyi LK, Auger KR, and Dinarello CA: Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest, 78:1432-1438, 1986
11. Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, and Gimbrone MA: Interleukin-1 activation of vascular endothelium. Effects on procoagulant activity and leukocyte adhesion. Am J Pathol, 121: 394-403, 1985
12. Tamaru M, Tomura K, Sakamoto S, Tezuka K, Tamatani T, and Narumi S: Interleukin-1beta induces tissue- and cell type-specific expression of adhesion molecules in vivo. Arterioscler Thromb Vasc Biol, 18: 1292-1303, 1998
13. Moyer CF, Sajuthi D, Tulli H, and Williams JK: Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. Am J Pathol, 138: 951-960, 1991
14. Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, and Holt CM: Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol, 16: 1000-1006, 1996
15. Ohsuzu F: The roles of cytokines, inflammation and immunity in vascular diseases. J Atheroscler Thromb, 11: 313-321, 2004
16. Tedgui A and Mallat Z: Anti-inflammatory mechanisms in the vascular wall. Circ Res, 88: 877-887, 2001
17. Dinarello CA: The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med, 343: 732-734, 2000
18. Dewberry R, Holden H, Crossman D, and Francis S: Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol, 20: 2394-2400, 2000
19. Beasley D, McGuiggin ME, and Dinarello CA: Human vascular smooth muscle cells produce an intracellular form of interleukin-1 receptor antagonist. Am J Physiol, 269: C961-C968, 1995
20. Arend WP: Interleukin-1 receptor antagonist. Adv Immunol, 54: 167-227, 1993
21. Eisenberg SP, Evans R, Arend WP, Verderber E, Brewer MT, Hannum CH, and Thompson RC: Primary structure and functional expression from complementary-DNA of a human interleukn-1 receptor antagonist. Nature, 343: 341-346, 1990
22. Haskill S, Martin G, Van Le L, Morris J, Peace A, Bigler CF, Jaffe GJ, Hammerberg C, Spom SA, Fong S, Arend WP, and Ralph P: cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. Proc Natl Acad Sci USA, 88: 3681-3685, 1991
23. Butcher C, Steinkasserer A, Tejura S, and Lennard AC: Comparison of two promoters controlling expression of secreted or intracellular IL-1 receptor antagonist. J Immunol, 153: 701-711, 1994
24. Andersson J, Bjork L, Dinarello CA, Towbin H, and Andersson U: Lipopolysaccharide induces human interleukin-1 receptor antagonist and interleukin-1 production in the same cell. Eur J Immunol, 22: 2617-2623, 1992
25. Malyak M, Guthridge JM, Hance KR, Dower SK, Freed JH, and Arend WP: Characterization of a low molecular weight isoforms of IL-1 receptor antagonist. J Immunol, 161: 1997-2003, 1998
26. Arend WP, Malyak M, Guthridge CJ, and Gabay C: Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol, 16: 27-55, 1998
27. Dinarello CA: Interleukin-1 and interleukin-1 antagonism. Blood, 77: 1627-1652, 1991
28. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood, 87: 2095-2147, 1996
29. Wang X, Romanic AM, Yue TL, Feuerstein GZ, and Ohlstein EH: Expression of interleukin-1beta, interleukin-1 receptor, and interleukin-1 receptor antagonist mRNA in rat carotid artery after balloon angioplasty. Biochem Biophys Res Commun, 271: 138-143, 2000
30. Rectenwald JE, Moldawer LL, Huber TS, Seeger JM, and Ozaki CK: Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation, 102: 1697-1702, 2000
31. Isoda K, Shiigai M, Ishigami N, Matsuki T, Horai R, Nishikawa K, Kusuhara M, Nishida Y, Iwakura Y, and Ohsuzu F: Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury. Circulation, 108: 516-518, 2003
32. Faggin E, Puato M, Zardo L, Franch R, Millino C, Sarinella F, Pauletto P, Sartore S, and Chiavegato A: Smooth muscle-specific SM22 protein is expressed in the adventitial cells of the balloon-injuryed rabbit carotid artery. Arterioscler Thromb Vasc Biol, 19: 1393-1404, 1999
33. Li G, Chen S-J, Oparil S, Chen Y-F, and Thompson JA: Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after ballon injury of rat carotid artery. Circulation, 101: 1362-1365, 2000
34. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, and Nagai R: Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med, 8: 403-409, 2002
35. Elhage R, Maret A, Pieraggi MT, Thiers JC, Amal JF, and Bayard F: Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation, 97: 242-244, 1998
36. Devlin CM, Kuriakose G, Hirsch E, and Tabas I: Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci U S A, 99: 5280-6285, 2002
37. Francis SE, Camp NJ, Dewberry RM, Gunn J, Syrris P, Carter ND, Jeffery S, Kaski JC, Cumberland DC, Duff GW, and Crossman DC: Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation, 99: 861-866, 1999
38. Isoda K, Sawada S, Ishigami N, Matsuki T, Miyazaki K, Kusuhara M, Iwakura Y, and Ohsuzu F: Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 24: 1068-1073, 2004
39. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, Asano M, Moriwaki H and Seishima M: Lack of Interleukin-1β decreases the severity of atherosclerosis in apoE-deficient mice. Arterioscler Thromb Vasc Biol, 23: 656-660, 2003
40. Gabay C and Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med, 340: 448-454, 1999
41. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, and Grunfeld C: Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res, 45: 1169-1196, 2004
42. Argiles JM, Lopez-Soriano FJ, Evans RD, and Williamson DH: Interleukin-1 and lipid metabolism in the rat. Biochem J, 259: 673-678, 1989
43. Feingold KR, Soued M, Adi S, Staprans I, Neese R, Shigenaga J, Doerrier W, Moser A, Dinarello CA, and Grunfeld C: Effect of interleukin-1 on lipid metabolism in the rat. Similarities to and differences from tumor necrosis factor. Arterioscler Thromb, 11: 495-500, 1991
44. Nonogaki K, Fuller GM, Fuentes NL, Moser AH, Staprans I, Grunfeld C, and Feingold KR: Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology, 136: 2143-2149, 1995
45. Malmendier CL, Lontie JF, Sculier JP, and Dubois DY: Modifications of plasma lipids, lipoproteins and apolipoproteins in advanced cancer patients treated with recombinant interleukin-2 and autologous lymphokine-activated killer cells. Atherosclerosis, 73: 173-180, 1988
46. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E 3rd, and Kufe DW: Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol, 6: 344-350, 1988
47. Starnes HF, Jr, Warren RS, Jeevanandam M, Gabrilove JL, Larchian W, Oettgen HF, and Brennan MF: Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest, 82: 1321-1325, 1988
48. Memon RA, Grunfeld C, Moser AH, and Feingold KR: Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology, 132: 2246-2253, 1993
49. Doerrier W, Feingold KR, and Grunfeld C: Cytokines induce catabolic effects in cultured adipocytes by multiple mechanisms. Cytokine, 6: 478-484, 1994
50. Zhang HH, Halbleib M, Ahmad F, Manganiello VC, and Greenberg AS: Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes, 51: 2929-2935, 2002
51. Greenberg AS, Shen WJ, Muliro K, Patel S, Souza SC, Roth RA, and Kraemer FB: 2001. Stimulation of lipolysis and hormone-sensitive lipase via the extracellular signal-regulated kinase pathway. J Biol Chem, 276: 45456-45461, 2001
52. Feingold KR, Marshall M, Gulli R, Moser AH, and Grunfeld C: Effect of endotoxin and cytokines on lipoprotein lipase activity in mice. Arterioscler Thromb, 14: 1866-1872, 1994
53. Hardardóttir I, Sipe J, Moser AH, Fielding CJ, Feingold KR, and Grünfeld C: LPS and cytokines regulate extra hepatic mRNA levels of apolipoproteins during the acute phase response in Syrian hamsters. Biochim Biophys Acta, 1344: 210-220 1997
54. Lanza-Jacoby S, Wong SH, Tabares A, Baer D, and Schneider T: Disturbances in the composition of plasma lipoproteins during gram-negative sepsis in the rat. Biochim Biophys Acta, 1124: 233-240, 1992
55. Feingold KR, Hardardottir I, Memon R, Krul EJ, Moser AH, Taylor JM, and Grunfeld C: Effect of endotoxin on cholesterol biosynthesis and distribution in serum lipoproteins in Syrian hamsters. J Lipid Res, 34: 2147-2158, 1993
56. Feingold KR, Pollock AS, Moser AH, Shigenaga JK, and Grunfeld C: Discordant regulation of proteins of cholesterol metabolism during the acute phase response. J Lipid Res, 36: 1474-1482, 1995
57. Xu N and Nilsson A: Endotoxin inhibits catabolism of low density lipoproteins in vivo: an experimental study in the rat. Scand J Clin Lab Invest, 56: 53-61, 1996
58. Feingold KR, Spady DK, Pollock AS, Moser AH, and Grunfeld C: Endotoxin, TNF, and IL-1 decrease cholesterol 7 alpha-hydroxylase mRNA levels and activity. J Lipid Res, 37: 223-228, 1996
59. Memon RA, Moser AH, Shigenaga JK, Grunfeld C, and Feingold KR: In vivo and in vitro regulation of sterol 27-hydroxylase in the liver during the acute phase response. Potential role of hepatocyte nuclear factor-1. J Biol Chem, 276: 30118-30126, 2001
60. Hartmann G, Cheung AK, and Piquette-Miller M: Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther, 303: 273-281, 2002
61. Vos TA, Hooiveld GJ, Koning H, Childs S, Meijer DK, Moshage H, Jansen PL, and Muller M: 199Upregulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology, 28: 1637-1644, 1998
62. Tygstrup N, Bangert K, Ott P, and Bisgaard HC: Messenger RNA profiles in liver injury and stress: a comparison of lethal and nonlethal rat models. Biochem Biophys Res Commun, 290: 518-525, 2002
63. Khovidhunkit W, Moser AH, Shigenaga JK, Grunfeld C, and Feingold KR: Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCGI in J774 murine macrophages: differential role of LXR. J Lipid Res, 44: 1728-1736, 2003
64. Pickup JC and Crook MA: Is type II diabetes mellitus a disease of the innate immune system? Diabetologia, 41: 1241-1248, 1998
65. Pradhan AD and Ridker PM: Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J, 23: 831-834, 2002
66. Huerta MG and Nadler JL: Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes. Curr Diab Rep, 2: 396-402, 2002
67. Grimble RF: 2002. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care, 5: 551-559, 2002
68. Yudkin JS, Kumari M, Humphries SE, and Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis, 148: 209-214, 2000
69. Isoda K, Sawada S, Makoto A, Matsuki T, Horai R, Kagata Y, Miyazaki K, Kusuhara M, Okazaki M, Matsubara O, Iwakura Y, and Ohsuzu F: Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver cholesterol metabolism in hypercholesterolemic mice. J Biol Chem, 280: 7002-7009, 2005
70. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, and Mangelsdorf DJ: Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell, 6: 507-515, 2000
71. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi, C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, and Kliewer SA: A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell, 6: 517-526, 2000
72. Bohan A, Chen WS, Denson LA, Held MA, and Boyer JL: Tumor necrosis factor α-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis. J Biol Chem, 278: 36688-36698, 2003
73. Li X, Commane M, Burns C, Vithalani K, Cao Z, and Stark GR: Mutant cells that do not respond to interleukin-1 (IL-1) reveal a novel role for IL-1 receptor-associated kinase. Mol Cell Biol, 19: 4643-4652, 1999
74. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, van der Heiden A, Itie A, Wakeham A, Khoo W, Sasaki T, Cao Z, Penninger JM, Paige CJ, Lacey DL, Dunstan CR, Boyle WJ, Goeddel DV, and Mak TW: TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev, 13: 1015-1024, 1999
75. Gupta S, Stravitz RT, Dent P, and Hylemon PB: Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. J Biol Chem, 276: 15816-15822, 2001
76. Miyake JH, Wang S-L, and Davis RA: Bile acid induction of cytokine expression by macrophages correlates with repression of hepatic cholesterol 7alpha-hydroxylase. J Biol Chem, 275: 21805-21808, 2000